These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 11375404

  • 1. Mutagenesis and derivatization of human vesicle monoamine transporter 2 (VMAT2) cysteines identifies transporter domains involved in tetrabenazine binding and substrate transport.
    Thiriot DS, Ruoho AE.
    J Biol Chem; 2001 Jul 20; 276(29):27304-15. PubMed ID: 11375404
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Individual residues contribute to multiple differences in ligand recognition between vesicular monoamine transporters 1 and 2.
    Finn JP, Edwards RH.
    J Biol Chem; 1997 Jun 27; 272(26):16301-7. PubMed ID: 9195934
    [Abstract] [Full Text] [Related]

  • 4. Chimeric vesicular monoamine transporters identify structural domains that influence substrate affinity and sensitivity to tetrabenazine.
    Peter D, Vu T, Edwards RH.
    J Biol Chem; 1996 Feb 09; 271(6):2979-86. PubMed ID: 8621690
    [Abstract] [Full Text] [Related]

  • 5. High-efficiency expression and characterization of the synaptic-vesicle monoamine transporter from baculovirus-infected insect cells.
    Sievert MK, Thiriot DS, Edwards RH, Ruoho AE.
    Biochem J; 1998 Mar 01; 330 ( Pt 2)(Pt 2):959-66. PubMed ID: 9480916
    [Abstract] [Full Text] [Related]

  • 6. Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice.
    Kilbourn MR, Kuszpit K, Sherman P.
    Synapse; 2000 Mar 15; 35(4):250-5. PubMed ID: 10657034
    [Abstract] [Full Text] [Related]

  • 7. Multiple residues contribute independently to differences in ligand recognition between vesicular monoamine transporters 1 and 2.
    Finn JP, Edwards RH.
    J Biol Chem; 1998 Feb 13; 273(7):3943-7. PubMed ID: 9461580
    [Abstract] [Full Text] [Related]

  • 8. Peptide mapping of the [125I]Iodoazidoketanserin and [125I]2-N-[(3'-iodo-4'-azidophenyl)propionyl]tetrabenazine binding sites for the synaptic vesicle monoamine transporter.
    Sievert MK, Ruoho AE.
    J Biol Chem; 1997 Oct 10; 272(41):26049-55. PubMed ID: 9325342
    [Abstract] [Full Text] [Related]

  • 9. Characterization of high-affinity [3H]TBZOH binding to the human platelet vesicular monoamine transporter.
    Zucker M, Weizman A, Rehavi M.
    Life Sci; 2001 Sep 28; 69(19):2311-7. PubMed ID: 11669473
    [Abstract] [Full Text] [Related]

  • 10. Regulation of rat brain vesicular monoamine transporter by chronic treatment with ovarian hormones.
    Rehavi M, Goldin M, Roz N, Weizman A.
    Brain Res Mol Brain Res; 1998 Jun 01; 57(1):31-7. PubMed ID: 9630494
    [Abstract] [Full Text] [Related]

  • 11. Lobeline displaces [3H]dihydrotetrabenazine binding and releases [3H]dopamine from rat striatal synaptic vesicles: comparison with d-amphetamine.
    Teng L, Crooks PA, Dwoskin LP.
    J Neurochem; 1998 Jul 01; 71(1):258-65. PubMed ID: 9648873
    [Abstract] [Full Text] [Related]

  • 12. Identification of residues involved in substrate recognition by a vesicular monoamine transporter.
    Merickel A, Rosandich P, Peter D, Edwards RH.
    J Biol Chem; 1995 Oct 27; 270(43):25798-804. PubMed ID: 7592763
    [Abstract] [Full Text] [Related]

  • 13. Assessment of extrastriatal vesicular monoamine transporter binding site density using stereoisomers of [11C]dihydrotetrabenazine.
    Koeppe RA, Frey KA, Kuhl DE, Kilbourn MR.
    J Cereb Blood Flow Metab; 1999 Dec 27; 19(12):1376-84. PubMed ID: 10598942
    [Abstract] [Full Text] [Related]

  • 14. Kinetic evaluation of [11C]dihydrotetrabenazine by dynamic PET: measurement of vesicular monoamine transporter.
    Koeppe RA, Frey KA, Vander Borght TM, Karlamangla A, Jewett DM, Lee LC, Kilbourn MR, Kuhl DE.
    J Cereb Blood Flow Metab; 1996 Nov 27; 16(6):1288-99. PubMed ID: 8898703
    [Abstract] [Full Text] [Related]

  • 15. Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter.
    Erickson JD, Schafer MK, Bonner TI, Eiden LE, Weihe E.
    Proc Natl Acad Sci U S A; 1996 May 14; 93(10):5166-71. PubMed ID: 8643547
    [Abstract] [Full Text] [Related]

  • 16. Amino- and amido-tetrabenazine derivatives: synthesis and evaluation as potential ligands for the vesicular monoamine transporter.
    Canney DJ, Kung MP, Kung HF.
    Nucl Med Biol; 1995 May 14; 22(4):527-35. PubMed ID: 7550031
    [Abstract] [Full Text] [Related]

  • 17. Reserpine or chronic paroxetine treatments do not modify the vesicular monoamine transporter 2 expression in serotonin-containing regions of the rat brain.
    Vilpoux C, Leroux-Nicollet I, Naudon L, Raisman-Vozari R, Costentin J.
    Neuropharmacology; 2000 Apr 03; 39(6):1075-82. PubMed ID: 10727718
    [Abstract] [Full Text] [Related]

  • 18. Reserpine- and tetrabenazine-sensitive transport of (3)H-histamine by the neuronal isoform of the vesicular monoamine transporter.
    Erickson JD, Eiden LE, Schafer MK, Weihe E.
    J Mol Neurosci; 1995 Apr 03; 6(4):277-87. PubMed ID: 8860238
    [Abstract] [Full Text] [Related]

  • 19. Modification of the pH profile and tetrabenazine sensitivity of rat VMAT1 by replacement of aspartate 404 with glutamate.
    Steiner-Mordoch S, Shirvan A, Schuldiner S.
    J Biol Chem; 1996 May 31; 271(22):13048-54. PubMed ID: 8662678
    [Abstract] [Full Text] [Related]

  • 20. Lobeline analogs with enhanced affinity and selectivity for plasmalemma and vesicular monoamine transporters.
    Miller DK, Crooks PA, Zheng G, Grinevich VP, Norrholm SD, Dwoskin LP.
    J Pharmacol Exp Ther; 2004 Sep 31; 310(3):1035-45. PubMed ID: 15121762
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.